スルファメトキシピラジン
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/08/01 18:28:40」(JST)
[Wiki en表示]
|
Systematic (IUPAC) name |
4-Amino-N-(3-methoxypyrazinyl)benzenesulfonamide
|
Clinical data |
Trade names |
Eadazine, Kelfizina, Kelfizine W, Longum |
AHFS/Drugs.com |
International Drug Names |
Routes of
administration |
Oral[1] |
Pharmacokinetic data |
Protein binding |
60 to 80%[1] |
Biological half-life |
60 to 65 hours[1] |
Excretion |
Urinary[1] |
Identifiers |
CAS Registry Number |
152-47-6 Y |
ATC code |
J01ED02 QJ01EQ19 |
PubChem |
CID: 9047 |
DrugBank |
DB00664 Y |
ChemSpider |
8695 Y |
UNII |
T6BL4ZC15G Y |
KEGG |
D01216 Y |
Synonyms |
Sulfametopyrazine |
Chemical data |
Formula |
C11H12N4O3S |
Molecular mass |
280.304 g/mol |
SMILES
-
O=S(=O)(Nc1nccnc1OC)c2ccc(N)cc2
|
InChI
-
InChI=1S/C11H12N4O3S/c1-18-11-10(13-6-7-14-11)15-19(16,17)9-4-2-8(12)3-5-9/h2-7H,12H2,1H3,(H,13,15) Y
-
Key:KXRZBTAEDBELFD-UHFFFAOYSA-N Y
|
Y (what is this?) (verify) |
Sulfalene (INN, USAN) or sulfametopyrazine (BAN) is a long-acting sulfonamide antibacterial used for the treatment of chronic bronchitis, urinary tract infections and malaria.[2][3] There are only two countries in which it is currently still marketed: Thailand and Ireland.[3]
Synthesis
Sulfalene synthesis:
GB 928151 U.S. Patent 3,098,069 [4]
See also
References
- ^ a b c d "Sulfalene". MIMS Drug Information System. Retrieved 26 August 2011.
- ^ DrugBank DB00664
- ^ a b Brayfield, A, ed. (9 May 2013). "Sulfametopyrazine". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 28 March 2014.
- ^ Camerino, B.; Palamidessi, G., Gazz. Chim. Ital., (1960) 90, 1815.
Antibacterials: nucleic acid inhibitors (J01E, J01M)
|
|
Antifolates
(inhibits
purine metabolism,
thereby inhibiting
DNA and RNA synthesis) |
DHFR inhibitor |
- 2,4-Diaminopyrimidine
- Trimethoprim#
- Brodimoprim
- Tetroxoprim
- Iclaprim†
|
|
Sulfonamides
(DHPS inhibitor) |
Short-
acting |
- Sulfaisodimidine
- Sulfamethizole
- Sulfadimidine
- Sulfapyridine
- Sulfafurazole
- Sulfanilamide
- Sulfathiazole
- Sulfathiourea
|
|
Intermediate-
acting |
- Sulfamethoxazole
- Sulfadiazine#
- Sulfamoxole
|
|
Long-
acting |
- Sulfadimethoxine
- Sulfadoxine
- Sulfalene
- Sulfametomidine
- Sulfametoxydiazine
- Sulfamethoxypyridazine
- Sulfaperin
- Sulfamerazine
- Sulfaphenazole
- Sulfamazone
|
|
Other/ungrouped |
- Sulfacetamide
- Sulfadicramide
- Sulfametrole
|
|
|
Combinations |
- Trimethoprim/sulfamethoxazole#
|
|
|
Topoisomerase
inhibitors/
quinolones/
(inhibits
DNA replication) |
1st g. |
- Cinoxacin‡
- Flumequine
- Nalidixic acid
- Oxolinic acid
- Pipemidic acid
- Piromidic acid
- Rosoxacin
|
|
Fluoro-
quinolones |
2nd g. |
- Ciprofloxacin#
- Enoxacin‡
- Fleroxacin‡
- Lomefloxacin
- Nadifloxacin
- Ofloxacin
- Norfloxacin
- Pefloxacin
- Rufloxacin
|
|
3rd g. |
- Balofloxacin
- Grepafloxacin‡
- Levofloxacin
- Pazufloxacin
- Sparfloxacin‡
- Temafloxacin‡
- Tosufloxacin
|
|
4th g. |
- Besifloxacin
- Clinafloxacin†
- Garenoxacin
- Gemifloxacin
- Moxifloxacin
- Gatifloxacin‡
- Sitafloxacin
- Trovafloxacin‡/Alatrofloxacin‡
- Prulifloxacin
|
|
Vet. |
- Danofloxacin
- Difloxacin
- Enrofloxacin
- Ibafloxacin
- Marbofloxacin
- Orbifloxacin
- Pradofloxacin
- Sarafloxacin
|
|
Related (DG) |
- Aminocoumarins: Novobiocin
|
|
|
|
Anaerobic DNA
inhibitors |
Nitro- imidazole derivatives |
- Metronidazole#
- Tinidazole
- Ornidazole
|
|
Nitrofuran derivatives |
- Nitrofurantoin#
- Furazolidone‡
- Nifurtoinol
|
|
|
RNA synthesis |
Rifamycins/
RNA polymerase |
- Rifampicin#
- Rifabutin
- Rifapentine
- Rifaximin
|
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Index of bacterial disease
|
|
Description |
|
|
Disease |
- Gram-positive firmicutes
- Gram-positive actinobacteria
- Gram-negative proteobacteria
- Gram-negative non-proteobacteria
- Cholera
- Tuberculosis
|
|
Treatment |
- Antibiotics
- cell wall
- nucleic acid
- mycobacteria
- protein synthesis
- other
- Antibodies
|
|
|
English Journal
- Development of a simple, rapid, and robust liquid chromatographic method for the simultaneous determination of sulfalene, sulfadoxine, and pyrimethamine in tablets.
- Mwalwisi YH1, Hoellein L2, Kaale E3, Holzgrabe U4.
- Journal of pharmaceutical and biomedical analysis.J Pharm Biomed Anal.2016 Sep 10;129:558-570. doi: 10.1016/j.jpba.2016.07.044. Epub 2016 Jul 30.
- PMID 27505128
- Consecutive oral administration of Bifidobacterium longum MM-2 improves the defense system against influenza virus infection by enhancing natural killer cell activity in a murine model.
- Kawahara T1, Takahashi T, Oishi K, Tanaka H, Masuda M, Takahashi S, Takano M, Kawakami T, Fukushima K, Kanazawa H, Suzuki T.
- Microbiology and immunology.Microbiol Immunol.2015 Jan;59(1):1-12. doi: 10.1111/1348-0421.12210.
- PMID 25400245
- Discovery of lipids from B. longum subsp. infantis using whole cell MALDI analysis.
- Timmer MS1, Sauvageau J, Foster AJ, Ryan J, Lagutin K, Shaw O, Harper JL, Sims IM, Stocker BL.
- The Journal of organic chemistry.J Org Chem.2014 Aug 15;79(16):7332-41. doi: 10.1021/jo501016c. Epub 2014 Aug 1.
- PMID 25032516
Japanese Journal
- 非定型抗酸菌に関する研究:第10報非定型抗酸菌症の発生機序に関する一実験
- 電量滴定による医薬品の分析(第2報) : スルファメトキシピラジンの電量滴定
- Sulfamethoxypyrazine(Sulfalene)に関する研究
Related Links
- Sulfamethoxypyrazine - Health Forums ... Recent Forum Posts What Side Effects Did You Experience With Sulfamethoxypyrazine? Can I Drink Some Beers With Sulfamethoxypyrazine? What Is the Active Ingredient In ...
- SULFAMETHOXYPYRAZINE ; Cat no.: API0004273 ; CAS no: 152-47-6 ; Therapeutic: ; Indication: ; Use: API ; Target: Change Language English Afrikaans - Afrikaans Albanian - Shqiptar Arabic - العربية Armenian - Հայերեն ...
Related Pictures
★リンクテーブル★
[★]
- 英
- sulfalene
- 同
- スルファメトキシピラジン sulfamethoxypyrazine、スルファメトピラジン sulfametopyrazine
- 商
- ケルヘチーナ
[★]
- 英
- sulfamethoxypyrazine
- 関
- スルファレン